Drug-Resistant Tuberculosis (DR-TB) occurs when Mycobacterium tuberculosis strains develop resistance to standard anti-TB drugs, such as isoniazid and rifampicin, posing a significant challenge in Ghana. This condition, including multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) forms, requires specialized treatment and urgent referral to advanced care facilities to manage effectively and limit transmission.
🦠 Overview and Pathophysiology
DR-TB arises from genetic mutations, often due to incomplete treatment or poor adherence:
Causes
- Resistance: Mutations in M. tuberculosis genome
- Risk Factors: Prior TB treatment, HIV co-infection, irregular drug supply
- Transmission: Person-to-person via airborne droplets
Types
- MDR-TB: Resistant to isoniazid and rifampicin
- XDR-TB: MDR plus resistance to fluoroquinolones and second-line injectables
- Key Point: Higher mortality and treatment complexity
🔍 Clinical Presentation
Symptoms are similar to drug-susceptible TB but may persist or worsen despite treatment:
Symptoms
Pulmonary: Persistent cough (>3 weeks), hemoptysis, chest pain
Systemic: Fever, night sweats, significant weight loss
Extrapulmonary: Lymph node enlargement, bone pain (if disseminated)
Signs
Respiratory: Crackles, consolidation on auscultation
General: Cachexia, lymphadenopathy
Other: Signs of treatment failure (e.g., no improvement after 2 months)
- Failure to respond to standard TB regimen
- Severe hemoptysis or respiratory failure
- Neurological signs (if CNS involvement)
🧪 Diagnosis
Confirm resistance with advanced testing:
Investigations
First-Line: GeneXpert MTB/RIF (detects rifampicin resistance)
Confirmatory: Line Probe Assay (LPA), culture with drug susceptibility testing (DST)
Imaging: Chest X-ray or CT for extent of disease
Supportive: HIV test, liver/renal function tests
💊 Treatment
Longer, more complex regimens are required, managed by specialists.
Non-Pharmacological
Isolation: Strict respiratory isolation
Nutrition: High-protein diet to support recovery
Counseling: Emphasize adherence and side effect reporting
MDR-TB Regimen
- Duration: 9-12 months (intensive phase) + 12-18 months (continuation)
- Drugs: Levofloxacin, bedaquiline, linezolid, cycloserine, plus an injectable (e.g., amikacin) initially
- Key Point: Tailored based on DST results
XDR-TB Regimen
- Duration: 18-24 months
- Drugs: Bedaquiline, linezolid, delamanid, plus other oral agents (e.g., clofazimine) based on resistance pattern
- Key Point: Requires expert management
HIV Co-Infection
- Approach: Coordinate TB and ART regimens
- Caution: Avoid drug interactions (e.g., rifampicin with certain ARVs)
- Monitor for ototoxicity (injectables), neuropathy (linezolid), and QT prolongation (bedaquiline)
- DOTS-Plus strategy recommended
- Refer all cases to national TB program or specialized centers
🤰 Special Populations
Adjust management based on vulnerability:
Children
Dose: Weight-based, use pediatric formulations
Focus: Monitor growth and adherence
Pregnancy
Safe Drugs: Levofloxacin, linezolid (with caution)
Avoid: Aminoglycosides, bedaquiline (teratogenicity risk)
Support: Multidisciplinary care
🚨 Referral Criteria
- All confirmed or suspected DR-TB cases
- Severe adverse drug reactions
- Extrapulmonary or complicated cases (e.g., CNS TB)
Refer to national TB reference laboratories or treatment centers.
🧠 Key Takeaways
- ✅ Diagnose Accurately: Use GeneXpert and DST
- ✅ Specialized Treatment: MDR/XDR regimens, 9-24 months
- ✅ Adherence: DOTS-Plus to prevent further resistance
- ✅ Monitor: Toxicity and treatment response
- ✅ Special Care: Adjust for children and pregnancy
- ✅ Refer: All cases to expert facilities